Roche Holding AG Basel American Depositary Shares (OP:RHHBY)

52.25 -0.10 (-0.19%)

Delayed Quote Updated: 3:59 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding AG Basel American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Positive Phase III Data for Genentech’s Gazyva Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

November 03, 2025

From Genentech

Via Business Wire

AI: The Pharmaceutical Sector’s New Catalyst for a Healthier Future

October 31, 2025

The pharmaceutical industry is in the midst of a profound and rapid transformation, driven by the pervasive integration of Artificial Intelligence (AI). What was once a futuristic concept is, by late...

Via TokenRing AI

Positive Phase III Results for Genentech’s Gazyva in Children and Young Adults With Idiopathic Nephrotic Syndrome

October 28, 2025

From Genentech

Via Business Wire

Top 3 Health Care Stocks You'll Regret Missing In October ↗

October 21, 2025

Via Benzinga

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results ↗

October 20, 2025

Exelixis stock dips after Phase 3 data show modest survival gains from zanzalintinib and Tecentriq combo in colorectal cancer patients.

Via Benzinga

S&P 500's Resurgence: A Deep Dive into Market Dynamics and Future Trajectories

October 23, 2025

The S&P 500 has staged a remarkable rebound, soaring to unprecedented highs in late 2025 following a period of significant sell-off earlier in the year. This resurgence, driven by a powerful confluence...

Via MarketMinute

Topics Artificial Intelligence Bonds Economy

Top 1% Celcuity Shoots To Record High On Roche-Rivaling Breast Cancer Results ↗

October 20, 2025

The company said its breast cancer treatment delayed progression for a median of 19.7 months in some patients.

Via Investor's Business Daily

Topics Government

Rapt Therapeutics, Outperforming 98% Of All Stocks, Skyrockets After Topping Roche ↗

October 20, 2025

The company took on Roche's Xolair in a 16-week study of patients with a chronic hives disorder.

Via Investor's Business Daily

Genentech’s Tecentriq Showed Significant Overall and Disease-Free Survival Benefits in Bladder Cancer With ctDNA-Guided Treatment

October 20, 2025

From Genentech

Via Business Wire

FDA Approves Genentech’s Gazyva for the Treatment of Lupus Nephritis

October 20, 2025

From Genentech

Via Business Wire

Genentech’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People With ER-Positive Advanced Breast Cancer

October 18, 2025

From Genentech

Via Business Wire

Genentech Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

October 17, 2025

From Genentech

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: 89bio, Inc. (Nasdaq - ETNB), Barinthus Biotherapeutics plc (Nasdaq - BRNS), Verint Systems Inc. (Nasdaq - VRNT), Dayforce, Inc. (NYSE- DAY)

October 16, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity ↗

October 16, 2025

William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long-term growth for its therapy pipeline.

Via Benzinga

Genentech Expands Xofluza® Access and Affordability for Upcoming Flu Season With Direct-to-Patient Launch

October 16, 2025

From Genentech

Via Business Wire

Merck's Keytruda Plus Chemo Regimen Shows Overall Survival Benefit In Recurrent Ovarian Cancer Patients ↗

October 16, 2025

Merck's KEYNOTE-B96 trial shows Keytruda with chemotherapy improves survival in platinum-resistant recurrent ovarian cancer with a consistent safety profile.

Via Benzinga

FDA Approves Alzheimer’s Test Developed By Roche In Collaboration With Eli Lilly ↗

October 13, 2025

The blood-based test is aimed at aiding the initial assessment for Alzheimer’s disease and other causes of cognitive decline in the primary-care setting in patients aged 55 and older.

Via Stocktwits

Genentech Data at ESMO 2025 Showcase Advances in Science and Cancer Care Across Multiple Tumor Types

October 13, 2025

From Genentech

Via Business Wire

Novo Nordisk Bulks Up Its Obesity-Tied Portfolio With $4.7 Billion Buyout ↗

October 09, 2025

The deal follows Roche's plan to buy 89bio, another MASH-focused biotech company.

Via Investor's Business Daily

Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market ↗

October 09, 2025

Roche has a promising GLP-1 drug that is entering phase 3 trials.

Via The Motley Fool

October 08, 2025

From Brodsky & Smith LLC

Via GlobeNewswire

FDA Greenlights Jazz and Roche's Zepzelca-Tecentriq for ES-SCLC Maintenance, Reshaping Lung Cancer Treatment Landscape

October 03, 2025

In a pivotal moment for oncology, the U.S. Food and Drug Administration (FDA) on October 2, 2025, granted approval for the innovative combination of Jazz Pharmaceuticals' (NASDAQ: JAZZ) Zepzelca...

Via MarketMinute

FDA Approves Genentech’s Tecentriq Plus Lurbinectedin as First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

October 02, 2025

From Genentech

Via Business Wire

Generative AI Unleashes a New Era in Genome Editing, Outperforming Nature in Protein Design

October 02, 2025

London, UK – October 2, 2025 – In a monumental stride for biotechnology and medicine, generative artificial intelligence (AI) has achieved a scientific breakthrough, demonstrating an unprecedented...

Via TokenRing AI

Topics Artificial Intelligence

GSK Leaps Into Buy Zone On Surprise Departure Of CEO Emma Walmsley ↗

September 29, 2025

Shares had broke out earlier this month, but have floundered at the lower boundary of the chart pattern.

Via Investor's Business Daily

Trump's 100% Pharmaceutical Tariff: The $270 Billion Manufacturing War That Could Reshape Your Medicine Cabinet ↗

September 26, 2025

Trump’s sweeping 100% pharmaceutical tariff starting October 1 triggers massive $270 billion industry investment surge, creating clear stock market winners like Eli Lilly while foreign-de

Via Benzinga

Topics Government World Trade

Prediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From Now ↗

September 26, 2025

BigBear.ai is bigger than both of these AI-focused companies now. That could change.

Via The Motley Fool

Topics Artificial Intelligence

Trump Shocks Pharma With 100% Tariff On Imported Drugs Unless Companies Build In America ↗

September 25, 2025

Via Stocktwits

Topics Government

Eli Lilly Ends Bimagrumab Obesity Study Weeks After Launch ↗

September 25, 2025

On Wednesday, Eli Lilly & Co. (NYSE: LLY) ended a mid-stage study of its experimental drug bimagrumab in obesity patients with type 2 diabetes, just weeks after it began.

Via Benzinga

Genentech Presents New Data for Ocrevus and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025

September 24, 2025

From Genentech

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

38 39 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.